The market expects Dolby Laboratories (DLB) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known ...

Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected ...

MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ('Annovis' or the 'Company'), a late-stage clinical ...

The growing demand for smart home devices and the adoption of the latest technologies is increasing the demand for consumer ...

Discusses a case where a person alleged to have committed securities violations admitted to having offshore assets that are ...

Powers’ bewitching new novel shares more than a little of this duality. Although outwardly a book that seeks to do the same ...

Louisiana State Employees Retirement System decreased its stake in Dolby Laboratories, Inc. (NYSE:DLB – Free Report) by 2.4% ...

Nilotinib, a drug approved by the US Food and Drug Administration (FDA) to treat chronic myeloid leukemia, improved ...

The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval The award to CervoMed ...

Opens in a new tab or window The chronic myeloid leukemia drug nilotinib (Tasigna) improved biomarkers and cognitive outcomes ...

Dolby Laboratories, Inc. ( NYSE:DLB ), might not be a large cap stock, but it received a lot of attention from ...